{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T09:30:35Z","timestamp":1767173435629,"version":"build-2238731810"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"U.S.A. National Institutes of Health (NIH) through the International Clinical, Operational and Health Services Research and Training Award (ICOHRTA)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12889-017-4597-9","type":"journal-article","created":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T09:22:17Z","timestamp":1500456137000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cost-Effectiveness of isoniazid preventive therapy among HIV-infected patients clinicaly screened for latent tuberculosis infection in Dar es Salaam, Tanzania: A prospective Cohort study"],"prefix":"10.1186","volume":"18","author":[{"given":"Grace A.","family":"Shayo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dereck","family":"Chitama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Candida","family":"Moshiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Said","family":"Aboud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Bakari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferdinand","family":"Mugusi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,19]]},"reference":[{"issue":"8866","key":"4597_CR1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/0140-6736(93)91817-6","volume":"342","author":"JW Pape","year":"1993","unstructured":"Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet. 1993 Jul;342(8866):268\u201372.","journal-title":"Lancet"},{"key":"4597_CR2","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1097\/00002030-199818000-00014","volume":"12","author":"A Mwinga","year":"1998","unstructured":"Mwinga A, Hosp M, Quigley M, Mwaba P, Mugala BN, Nyirenda O, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS. 1998;12:2447\u201357.","journal-title":"AIDS"},{"key":"4597_CR3","first-page":"1","volume":"1","author":"C Akolo","year":"2010","unstructured":"Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons ( review ). Cochrane Libr. 2010;1:1\u201382.","journal-title":"Cochrane Libr"},{"issue":"5","key":"4597_CR4","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/QAD.0b013e328327964f","volume":"23","author":"JE Golub","year":"2009","unstructured":"Golub JE, Paul P, Mohapi L, Thsabangu N, Moshabela M, Struthers H, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS. 2009;23(5):631\u20136.","journal-title":"AIDS"},{"key":"4597_CR5","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/00002030-199903110-00009","volume":"13","author":"HC Bucher","year":"1999","unstructured":"Bucher HC, Griffith LE, Guyatt GH, Sudre P, Naef M, Sendi P, et al. Isoniazid prophylaxis for tuberculosis in HIV infection\u00a0: a meta-analysis of randomized controlled trials. AIDS. 1999;13:501\u20137.","journal-title":"AIDS"},{"issue":"10","key":"4597_CR6","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.5588\/ijtld.13.0571","volume":"18","author":"S Gupta","year":"2014","unstructured":"Gupta S, Abimbola T, Date A, Suthar AB, Bennett R, Sangrujee N, et al. Cost-effectiveness of the three I\u2019s for HIV\/TB and ART to prevent TB among people living with HIV. Int J Tuberc Lung Dis. 2014;18(10):1159\u201365.","journal-title":"Int J Tuberc Lung Dis."},{"issue":"Suppl 5","key":"4597_CR7","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1097\/01.aids.0000391010.02774.6f","volume":"24","author":"S Charalambous","year":"2010","unstructured":"Charalambous S, Grant AD, Innes C, Hoffmann CJ, Dowdeswell R, Pienaar J, et al. Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme. AIDS. 2010 [cited 2015 Jul 5];24(Suppl 5):S5\u201313.","journal-title":"AIDS"},{"issue":"8","key":"4597_CR8","first-page":"1038","volume":"13","author":"MA Bachhuber","year":"2009","unstructured":"Bachhuber MA, Gross R. Mortality benefi t of isoniazid preventive therapy in HIV-positive persons\u00a0: a simulation study SUMMARY. Int J Tuberc Lung Dis. 2009;13(8):1038\u201340.","journal-title":"Int J Tuberc Lung Dis"},{"key":"4597_CR9","unstructured":"WHO. Guidelines for intensified case finding isoniazid preventive therapy for people living with HIV in resource constrained settings 2011. Available from: http:\/\/whqlibdoc.who.int\/publications\/2011\/9789241500708_eng.pdf . Accessed 22 Jun 2012."},{"key":"4597_CR10","unstructured":"National AIDS Control Program (NACP) of the United Republic of Tanzania National Guidelines for the Management of HIV and AIDS. 2012. Available from: www.nacp.go.tz\/site\/download\/nationalguideline42012.pdf . Accessed 3 Apr 2014."},{"key":"4597_CR11","unstructured":"Namibia Ministry of health and social services. National Guidelines for the Management of Tuberculosis. 2011:185. Available from: http:\/\/www.who.int\/hiv\/pub\/guidelines\/namibia_tb.pdf . Accessed 17 July 2015."},{"issue":"4","key":"4597_CR12","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1164\/rccm.200404-478OC","volume":"170","author":"D Menzies","year":"2004","unstructured":"Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med. 2004;170(4):445\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"4597_CR13","doi-asserted-by":"publisher","unstructured":"Pho MT, Swaminathan S, Kumarasamy N, Losina E, Ponnuraja C, Uhler LM, et al. The cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in southern India: a trial-based analysis. PLoS One. 2012;7(4):e36001. doi: 10.1371\/journal.pone.0036001 .","DOI":"10.1371\/journal.pone.0036001"},{"issue":"12","key":"4597_CR14","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1097\/00002030-199908200-00016","volume":"13","author":"JC Bell","year":"1999","unstructured":"Bell JC, Rose DN, Sacks HS. Tuberculosis preventive therapy for HIV-infected people in sub-Saharan Africa is cost-effective. AIDS. 1999;13(12):1549\u201356.","journal-title":"AIDS"},{"issue":"2","key":"4597_CR15","first-page":"1023","volume":"3","author":"G Shayo","year":"2016","unstructured":"Shayo G, Moshiro C, Aboud S, Bakari M, Mugusi F. Tuberculosis incidence and all-cause mortality among human immunodeficiency virus-infected patients on Isoniazid preventive therapy in Dar Es Salaam, Tanzania. Austin J HIV\/AIDS Res. 2016;3(2):1023.","journal-title":"Austin J HIV\/AIDS Res"},{"key":"4597_CR16","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1186\/s12879-015-1085-7","volume":"15","author":"GA Shayo","year":"2015","unstructured":"Shayo GA, Moshiro C, Aboud S, Bakari M, Mugusi FM. Acceptability and adherence to Isoniazid preventive therapy in HIV-infected patients clinically screened for latent tuberculosis in Dar es salaam. Tanzania BMC Infect Dis. 2015;15:368.","journal-title":"Tanzania BMC Infect Dis"},{"key":"4597_CR17","unstructured":"Tanzania Ministry of Health and Social Welfare, National Guidelines for the Management of Tuberculosis in children. First Edit. Dar es Salaam; 2012. Available from: http:\/\/ihi.eprints.org\/3363\/1\/national_guidelines_for_the__management_of_tb_in_children_%281%29.pdf . Accessed 5 Jan 2014."},{"issue":"6","key":"4597_CR18","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/tmi.12307","volume":"19","author":"GA Shayo","year":"2014","unstructured":"Shayo GA, Minja LT, Egwaga S, Bakari M, Mugusi FM. Symptom-based screening tool in ruling out active tuberculosis among HIV-infected patients eligible for isoniazid preventive therapy in Tanzania. Tropical Med Int Health. 2014;19(6):726\u201333.","journal-title":"Tropical Med Int Health"},{"issue":"6","key":"4597_CR19","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1371\/journal.pone.0066312","volume":"8","author":"D Kostova","year":"2013","unstructured":"Kostova D, Reed C, Finelli L, Cheng PY, Gargiullo PM, Shay DK, et al. Influenza illness and hospitalizations averted by influenza vaccination in the United States, 2005-2011. PLoS One. 2013;8(6):2005\u201311.","journal-title":"PLoS One"},{"issue":"1","key":"4597_CR20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/2046-4053-3-47","volume":"3","author":"X Xu","year":"2014","unstructured":"Xu X, Nardini HKG, Ruger JP. Micro-costing studies in the health and medical literature\u00a0: protocol for a systematic review. Syst Rev. 2014;3(1):47.","journal-title":"Syst Rev"},{"key":"4597_CR21","doi-asserted-by":"crossref","unstructured":"Drummond M, Sculpher M, Torrance G, O\u2019Brien B, Stoddart G. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.","DOI":"10.1093\/oso\/9780198529446.001.0001"},{"key":"4597_CR22","unstructured":"Stop TB Partinership. Global Drug Facility (GDF). 2014. Available from http:\/\/www.stoptb.org\/gdf\/drugsupply\/procurement_notices_archive.asp . Accessed 20 May 2015."},{"key":"4597_CR23","unstructured":"Bank of Tanzania. Financial Markets-Foreign Exchange Markets. 2012. Available from: http:\/\/www.bot-tz.org\/financialmarkets\/FinancialMarkets.asp . Accessed 20 May 2015."},{"key":"4597_CR24","unstructured":"Bank of Tanzania. Indicative Foreign Exchange Market Rates. 2015 Available from: https:\/\/www.bot-tz.org\/FinancialMarkets\/ExchangeRates\/ShowExchangeRates.asp . Accessed 20 May 2015"},{"key":"4597_CR25","unstructured":"National AIDS Control Program (NACP) of the United Republic of Tanzania. National guidelines for the management of HIV and AIDS [Internet]. 2009. Available from: http:\/\/www.who.int\/hiv\/pub\/guidelines\/tanzania_art.pdf .\u00a0Accessed 20 Nov 2011."},{"key":"4597_CR26","first-page":"713","volume":"13","author":"BS Sutton","year":"2009","unstructured":"Sutton BS, Arias MS, Chheng P, Eang MT, Kimerling ME. The cost of intensifi ed case fi nding and isoniazid preventive therapy for HIV-infected patients in Battambang. Cambodia Int J. 2009;13:713\u20138.","journal-title":"Cambodia Int J"},{"issue":"3","key":"4597_CR27","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1097\/QAI.0000000000000783","volume":"70","author":"T Smith","year":"2015","unstructured":"Smith T, Samandari T, Abimbola T, Marston B, Sangrujee N. Cost-effectiveness of antiretroviral therapy and Isoniazid prophylaxis to reduce tuberculosis and death in people living with HIV in Botswana. J Acquir Immunodefic Syndr. 2015;70(3):e84\u201393.","journal-title":"J Acquir Immunodefic Syndr"},{"issue":"iii","key":"4597_CR28","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2471\/BLT.14.138206","volume":"93","author":"E Marseille","year":"2015","unstructured":"Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost \u2013 effectiveness of interventions\u00a0: alternative approaches. Bull World Health Organ. 2015;93(iii):118\u201324.","journal-title":"Bull World Health Organ"}],"updated-by":[{"DOI":"10.1186\/s12889-017-4709-6","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,9,22]],"date-time":"2017-09-22T00:00:00Z","timestamp":1506038400000}}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-017-4597-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T12:43:11Z","timestamp":1719319391000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-017-4597-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,19]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4597"],"URL":"https:\/\/doi.org\/10.1186\/s12889-017-4597-9","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,19]]},"article-number":"35"}}